PHENOTYPIC CONVERSION OF CULTURED MOUSE EMBRYO CELLS BY AZA PYRIMIDINE NUCLEOSIDES
PHENOTYPIC CONVERSION OF CULTURED MOUSE EMBRYO CELLS BY AZA PYRIMIDINE NUCLEOSIDES
复制标题
DOI:
10.1016/0012-1606(78)90273-7
复制
发表时间:
1978-01-01
影响因子:
2.7
通讯作者:
JONES, PA
中科院分区:
文献类型:
--
作者:
CONSTANTINIDES, PG;TAYLOR, SM;JONES, PA
Cells of the C3H/10T1/2CL8 [mouse embryo fibroblast] line, which are nonmyoblastic in nature, form functional myotubes when treated with low concentrations of 5-azacytidine [a drug used in cancer therapy]. They arise from the fusion of mononucleated precursors and not as a result of endoreplication. They accumulate histochemically detectable myosin ATPase activity and acetylcholine receptors capable of binding radioactively labeled .alpha.-bungarotoxin. The deoxy analog, 5-aza-2''-deoxycytidine, induced myogenic conversion at 1/10 of the maximally effective concentration of 5-azacytidine. The ability of both analogs to induce myotube formation and to cause cytotoxicity was strongly influenced by cotreatment with certain pyrimidine nucleosides. These effects were consistent with a requirement for metabolism of both aza compounds to phosphorylated derivatives and with a mechanism of action based on their incorporation into DNA. Concentrations of the analogs causing myogenic conversion did not substantially alter rates of DNA, RNA or protein synthesis as measured by precursor incorporation into intact cells. The induction of myotubes by 5-azacytidine in cells synchronized by 2 different methods required that treatment with the analog was carried out at a critical phase early in S phase. The mechanism of drug action appears to be linked to specific DNA synthesis.